Brown Brothers Harriman & Co. Has $72,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Brown Brothers Harriman & Co. increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 190.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 389 shares of the medical research company’s stock after acquiring an additional 255 shares during the period. Brown Brothers Harriman & Co.’s holdings in Charles River Laboratories International were worth $72,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CRL. Versant Capital Management Inc boosted its holdings in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the period. Tortoise Investment Management LLC grew its position in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares during the period. ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the fourth quarter valued at $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the third quarter worth $59,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of several analyst reports. UBS Group reaffirmed a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Barclays dropped their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $145.82 on Wednesday. Charles River Laboratories International, Inc. has a 52 week low of $145.66 and a 52 week high of $267.83. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market capitalization of $7.46 billion, a price-to-earnings ratio of 972.11, a PEG ratio of 4.54 and a beta of 1.45. The firm has a fifty day moving average of $163.95 and a two-hundred day moving average of $181.92.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.46 earnings per share. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).